Polycystic Kidney, Autosomal Dominant
Conditions
Brief summary
Primary Objective: To determine the effect of venglustat on the rate of total kidney volume (TKV) growth (Stage 1) and estimated glomerular filtration rate (eGFR) decline in participants at risk of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) (Stage 2). Secondary Objectives: * To determine the effect of venglustat on the rate of renal function decline (Stage 1) and on the rate of TKV growth (Stage 2). * To evaluate the pharmacokinetics (PK) of venglustat in ADPKD participants (Stages 1 and 2). * To determine the effect of venglustat on pain and fatigue, based on participant reported diary (Stages 1 and 2). * Safety/tolerability objectives: * To characterize the safety profile of venglustat (Stages 1 and 2). * To evaluate the effect of venglustat on mood using Beck Depression Inventory II (BDI-II) (Stages 1 and 2). * To evaluate the effect of venglustat on the lens by ophthalmological examination (Stages 1 and 2).
Detailed description
Study duration per participant was 26 months (maximal) that included a screening period of 15 days, run-in period of 2 weeks, a 24-month treatment period, and a follow-up 30 days after final dose of investigational medicinal product (IMP).
Interventions
DRUGVenglustat
Pharmaceutical form: capsule; Route of administration: oral
DRUGPlacebo
Pharmaceutical form: capsule; Route of administration: oral
Sponsors
Genzyme, a Sanofi Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Male or female adult with ADPKD with age at the time the consent was signed: 1. between 18 to 50 years (both inclusive) for participants from Stage 1. 2. between 18 to 50 years (both inclusive) for participants from Stage 2 with eGFR between 45 and 89.9 milliliters per minute per 1.73 meter square (mL/min/1.73 m\^2) during screening period.\* 3. between 18 to 55 years (both inclusive) for participants from Stage 2 with eGFR between 30 and 44.9 mL/min/1.73 m\^2 during screening period.\* * Diagnosis of ADPKD in participants with a family history would be based on unified Pei criteria. In the absence of a family history, the diagnosis would be based on the presence of renal cysts bilaterally, totaling at least 20, in the absence of findings suggestive of other cystic renal diseases. * Mayo Imaging Classification of ADPKD Class 1C, 1D or 1E\*\* \*\*Total kidney volume (TKV) had confirmed by a central reader prior to Visit 3. * Estimated glomerular filtration rate between 45 to 89.9 mL/min/1.73 m\^2 during screening period\* (Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] equation) for Stage 1. * Estimated glomerular filtration rate between 30 to 89.9 mL/min/1.73 m\^2 during screening period\* (CKD-EPI equation) for Stage 2. \*Eligibility would be confirmed by eGFR value from one of the two first pre-randomization eGFR measurements. * Stable treatment regimen of antihypertensive therapy for at least 30 days prior to the screening visit for hypertensive participant. * Able to read, comprehend, and respond to the study questionnaires. * Participant had given voluntary written informed consent before performance of any study related procedures not part of standard medical care. * Participant had no access to tolvaptan at the time of study start or tolvaptan was not indicated for treatment of participant according to treating physician (participant does not meet recommended criteria for treatment, refuses to initiate or does not tolerate treatment with tolvaptan). * The participants, if female of childbearing potential, must have had a negative blood pregnancy test (β-human chorionic gonadotropin \[β-hCG\]) at the screening visit and a negative urine pregnancy test at the baseline visit. * Female participants of childbearing potential and male participants must have had agreed to practice true abstinence in line with their preferred and usual lifestyle or to use double-contraceptive methods (including a highly effective method of contraception for female participants of childbearing potential) for the entire duration of the study and for at least 6 weeks for females and 90 days for males following their last dose of study drug.
Exclusion criteria
* Systolic blood pressure greater than (\>) 160 millimeters of Mercury (mmHg) at Run-in and Baseline visits. * Administration within 3 months prior to the screening visit of tolvaptan or other Polycystic Kidney Disease-modifying agents (somatostatin analogues). * Participation in another investigational interventional study or use of IMP, within 3 months or 5 half lives, whichever was longer, before randomization. * The participant had a positive result of any of the following tests: hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (anti HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti HIV1 and anti HIV2 Ab). Participants with a positive hepatitis B surface antibody (HBsAb) test were eligible if other criteria were met (i.e., negative tests for: HBsAg, hepatitis B core antibody \[HBcAb\]). Participants immune due to natural infection (positive hepatitis B surface antibody (HBsAb), negative hepatitis B surface antigen (HBsAg) and positive hepatitis B core antibody \[HBcAb\]) were eligible if they had negative hepatitis B vaccine (HBV) deoxyribonucleic acid (DNA) test. * A history of drug and/or alcohol abuse within the past year prior to the screening visit. A history of alcohol dependence within the 5 years prior to the screening visit. * The participant was scheduled for in-patient hospitalization including elective surgery, during the study. * The participant had a clinically significant, uncontrolled medical condition that, in the opinion of the investigator, would put the safety of the participant at risk through participation, or which would affect the efficacy or safety analysis if the condition exacerbated during the study, or that might significantly interfere with study compliance, including all prescribed evaluations and follow-up activities. * The participants, in the opinion of the investigator, was unable to adhere to the requirements of the study or unable to undergo study assessments (e.g., had contraindications to pupillary dilation or unable to undergo magnetic resonance imaging (MRI) \[For example: participant's weight exceeds weight capacity of the MRI, ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal/back tattoos, etc.\]). * Any country-related specific regulation that would prevent the participant from entering the study. * The participants did not adhere to treatment (less than \[\<\] 70 percent \[%\] compliance rate) in the run-in. * The participant had, according to World Health Organization (WHO) Grading, a cortical cataract greater than or equal to (\>=)one-quarter of the lens circumference (Grade cortical cataract-2 \[COR-2\]) or a posterior subcapsular cataract \>=2 millimeter (Grade posterior subcapsular cataract-2 \[PSC-2\]). Participant with nuclear cataracts would not be excluded. * The participant was then receiving potentially cataractogenic medications, including a chronic regimen (more frequently than every 2 weeks) of any route of corticosteroids (including medium and high potency topical steroids) or any medication that might cause cataract, according to the Prescribing Information. * The participant had received strong or moderate inducers or inhibitors of CYP3A4 within 14 days or 5 half-lives, whichever was longer, prior to randomization. This also included the consumption of grapefruit, grapefruit juice, or grapefruit containing products within 72 hours of starting venglustat administration. * The participant was pregnant, or lactating. * Liver enzymes (alanine aminotransferase /aspartate aminotransferase ) or total bilirubin \>2 times the upper limit of normal unless the participant had the diagnosis of Gilbert syndrome. Participants with the Gilbert syndrome should have had no additional symptoms or signs which suggested hepatobiliary disease and serum total bilirubin level no more than 3 milligrams per deciliter (mg/dL) (51 \[micromoles per Liter\] mcmol/L) with conjugated bilirubin less than 20% of the total bilirubin fraction. * Presence of severe depression as measured by Beck Depression Inventory-II (BDI-II) \>28 and/or a history of a major affective disorder within 1 year of the screening visit. * Known hypersensitivity to venglustat or any component of the excipients. The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Annualized Slope of Change in Total Kidney Volume (TKV) From Baseline to Month 18: Stage 1 | From Baseline to Month 18 | Total kidney volume is a measure for assessing disease progression in participants with ADPKD, a prognostic biomarker of renal function decline and progression to end-stage renal disease. Kidney volume was assessed using magnetic resonance imaging (MRI). The annualized slope of change in TKV (in percentage \[%\] per year) in each treatment group was obtained from the back-transformation of the mean slope of log10-transformed TKV obtained from the linear mixed effect model. The model included fix effects of treatment (venglustat 15 mg, venglustat 8 mg or placebo), mayo imaging classification (as per randomization stratification factor: class 1C versus 1D versus 1E), time (as continuous variable in years), treatment \* time interaction and mayo imaging classification \* time interaction and included random intercept and slope. |
| Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) From Baseline to Month 24: Combined Stage 1 and Stage 2 | From Baseline to Month 24 | An eGFR was used to measure level of kidney function and determine the stage of kidney disease in ADPKD participants. Baseline eGFR was defined for each participant as the average of eGFR values assessed prior or equal to first dose of study drug or randomization for participants randomized and not exposed. Annualized rate of change in eGFR in each treatment group was obtained from the linear mixed effect model including the fixed categorical effects of treatment group (venglustat 15 mg, venglustat 8 mg or placebo), mayo imaging classification (as per interactive response technology \[IRT\]: 1C, 1D, 1E), time (as continuous variable in years), treatment-by-time, mayo imaging classification-by-time, and included random intercept and slope. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score From Baseline to Month 18: Stage 1 | From Baseline to Month 18 | The BPI-SF is a validated, self-administered questionnaire designed to measure a participant's perceived level of pain. The BPI-SF consisted of 15 items that use a numeric rating scale (NRS) to assess pain severity and pain interference in the past 24 hours and the past week. BPI-SF Item 3 asks participants to Please rate your pain by marking the box beside the number that best describes your pain at its worst in the past 24 hours. The NRS ranged from 0 (no pain) to 10 (worst imaginable pain), where higher scores indicates greater intensity of pain. Least-squares (LS) means, and standard errors (SE) were estimated from mixed-effect model with repeated measures (MMRM) analysis. |
| Change in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score From Baseline to Month 24: Combined Stage 1 and Stage 2 | From Baseline to Month 24 | The BPI-SF is a validated, self-administered questionnaire designed to measure a participant's perceived level of pain. The BPI-SF consisted of 15 items that use a NRS to assess pain severity and pain interference in the past 24 hours and the past week. BPI-SF Item 3 asks participants to Please rate your pain by marking the box beside the number that best describes your pain at its worst in the past 24 hours. The NRS ranged from 0 (no pain) to 10 (worst imaginable pain), where higher scores indicate greater intensity of pain. LS means and SE were estimated from MMRM analysis. |
| Change in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI-SF)-Item 3 Scale Score From Baseline to Month 18: Stage 1 | From Baseline to Month 18 | The BFI-SF is a 10-item, validated, self-administered questionnaire that was originally developed to assess fatigue severity. The 10-items were measured on a 0-10 scale, with 0 being 'does not interfere' and 10 being 'completely interferes.' BFI - Item 3 asks participants to 'Please rate your fatigue (weariness, tiredness) by circling the one number that best describes your worst level of fatigue during the past 24 hours. The NRS ranged from 0 (no fatigue) to 10 (worst imaginable fatigue). Higher global scores were associated with more severe fatigue. LS means and SE were estimated from MMRM analysis. |
| Change in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI-SF)-Item 3 Scale Score From Baseline to Month 24: Combined Stage 1 and Stage 2 | From Baseline to Month 24 | The BFI-SF is a 10-item, validated, self-administered questionnaire that was originally developed to assess fatigue severity. The 10-items were measured on a 0-10 scale, with 0 being 'does not interfere' and 10 being 'completely interferes.' BFI - Item 3 asks participants to Please rate your fatigue (weariness, tiredness) by circling the one number that best describes your worst level of fatigue during the past 24 hours. The NRS ranged from 0 (no fatigue) to 10 (worst imaginable fatigue). Higher global scores were associated with more severe fatigue. LS means and SE were estimated from MMRM analysis. |
| Pharmacokinetics: Plasma Concentration of Venglustat: Stage 1 | Day 1: 3 hours Post-Dose, Month 1: Pre-Dose and 3 hours Post-Dose, Month 6: Pre-Dose, Month 18: Pre-Dose | Venglustat plasma concentrations was determined using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Data for this outcome measure was not planned to be collected and analyzed for placebo arm. |
| Pharmacokinetics: Plasma Concentration of Venglustat: Stage 2 | Month 1: Pre-dose and 3 hours Post-dose | Venglustat plasma concentrations was determined using a validated LC-MS/MS method. Data for this outcome measure was not planned to be collected and analyzed for placebo arm. |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs): Stage 1 | From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier | An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. A serious adverse event (SAE) was any untoward medical occurrence that at any dose: results in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was a medically important event. TEAEs were AEs that developed, worsened or became serious during the treatment-emergent (TE) period (defined as the time from the first investigational medicinal product \[IMP\] administration up to the last IMP administration in EFC15392 study + 30 days or up to the first visit in LTS15823 study, whichever comes earlier). |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs): Combined Stage 1 and Stage 2 | From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier | An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. SAE was any untoward medical occurrence that at any dose: results in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was a medically important event. TEAEs were AEs that developed, worsened or became serious during the TE period (defined as the time from the first IMP administration up to the last IMP administration in EFC15392 study + 30 days or up to the first visit in LTS15823 study, whichever comes earlier). |
| Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Month 24: Stage 1 | From Baseline to Month 24 | An eGFR was used to measure level of kidney function and determine the stage of kidney disease in ADPKD participants. Baseline eGFR was defined for each participant as the average of eGFR values assessed prior or equal to first dose of study drug or randomization for participants randomized and not exposed. Annualized rate of change in eGFR was obtained from the linear mixed effect model including the fixed categorical effects of treatment group, mayo imaging classification (as per IRT), time (as continuous variable in years), treatment-by-time, mayo imaging classification-by-time, and included random intercept and slope. Due to early termination of study for futility, the two-steps analysis initially planned was not applicable, then the annualized rate of change from baseline in eGFR in Stage 1 population were assessed using all data available up to database lock (i.e., including Month 24 assessment). As this is a slope, it allowed to have more data and to reduce variability. |
| Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier | Criteria for potentially clinically significant abnormalities: Glucose: \<=3.9 millimoles per liter (mmol/L) and \<lower limit of normal (LLN): \>=11.1 mmol/L (unfasted); \>=7 mmol/L (fasted); Albumin:\<=25 g/L; Sodium: \<=129 mmol/L; \>=160 mmol/L; Potassium: \<3 mmol/L; \>=5.5 mmol/L; Chloride: \<80 mmol/L, \>115 mmol/L; Creatinine: \>=150 micro millimoles per liter (mcmol/L) (Adults); \>=30% change from Baseline; \>=100% change from Baseline, Urea Nitrogen: \>=17 mmol/L; Alanine Aminotransferase (ALT): \>3 ULN; Aspartate Aminotransferase (AST): \>3 ULN; Alkaline Phosphatase: \>1.5 ULN; Total Bilirubin: \>1.5 ULN, \>2 ULN; ALT \>3 ULN and Bilirubin \>2 ULN; and Direct Bilirubin \>35% Bilirubin and Bilirubin \>1.5 ULN. |
| Number of Participants With Potentially and Clinically Significant Abnormalities: Urinalysis: Combined Stage 1 and Stage 2 | From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier | Criteria for potentially clinically significant abnormalities: Urine pH: \<=4.6 and \>=8. |
| Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier | Criteria for potentially clinically significant abnormalities: Sitting Systolic Blood Pressure: \<=95 millimeters of Mercury (mmHg) and decrease from Baseline \>=20 mmHg; \>=160 mmHg and increase from Baseline \>=20 mmHg; Sitting Diastolic Blood Pressure: \<=45 mmHg and decrease from Baseline \>=10 mmHg, \>=110 mmHg and increase from Baseline \>=10 mmHg; Sitting Heart Rate: \<=50 beats/minute and decrease from Baseline \>=20 beats/minute; \>=120 beats/minute and increase from Baseline \>=20 beats/minute; and Weight: \>=5% decrease from Baseline; \>=5% increase from Baseline. |
| Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier | Criteria for potentially clinically significant abnormalities: Heart Rate: \<50 beats/minute; \<50 beats/minute and decrease from Baseline \>=20 beats/minute; \<40 beats/minute; \<40 beats/minute and decrease from Baseline \>=20 beats/min; \<30 beats/minute; \>90 beats/minute; \>90 beats/minute and increase from Baseline \>=20 beats/minute; \>100 beats/minute; \>100 beats/minute and increase from Baseline \>=20 beats/minute; \>120 beats/minute; \>120 beats/minute, increase from Baseline \>=20 beats/minute; PR Interval: \>200 milliseconds (msec); \>200 msec and increase from Baseline \>=25%; \>220 msec, \>240 msec; QRS Interval: \>110 msec; \>110 msec and increase from Baseline \>=25%; \>120 msec; \>120 msec and increase from Baseline \>=25%; QT Interval: \>500 msec; QT corrected for heart rate (QTc) Bazett: \>450 msec; \>480 msec; increase from Baseline (30-60) msec; increase from Baseline \>60 msec; QTc Fridericia: \>450 msec; \>480 msec; increase from Baseline (30-60) msec and increase from Baseline \> 60 msec. |
| Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline, Month 18, Month 24 | Physical examination included: Head, Heart, Lung, Abdomen, Musculo/Skeletal, Skin, and Mental Status. Abnormality in physical examination was based on investigator's discretion. Results are based on the treatment emergent period which was defined as time from the first IMP administration up to the last IMP administration in EFC15392 study + 30 days or up to the first visit in LTS15823 study, whichever comes earlier. |
| Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Baseline, Months 3, 6, 9, 12, 15, 18, 21, and 24, Last on-treatment value up to last IMP + 1 day (anytime during the maximum duration of 25 months) | The Beck Depression Inventory-II (BDI-II) is a 21-item questionnaire used to assess depression. Most items are rated on a 4-point scale from 0 to 3, and a few items are rated on a 7-point scale. Individual item scores are added to get a total BDI-II score from 0 to 63. The higher the total score, the more severe the depression, and the lower the total score, the less severe the depression. |
| Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier | Worsening of lens opacity classification system (LOCS) III score or World Health Organization (WHO) grade in nuclear opacification, cortical opacification and posterior subcapsular opacification were assessed for 'Any eye', 'Unilateral' and 'Bilateral' separately. A participant could be counted in all the 3 categories. In each category, the worst case was taken into account. To be evaluable for 'Any', a participant had to have at least one eye evaluable, whereas, for 'Unilateral' and 'Bilateral', a participant had to have both eyes evaluable. Therefore, the sum of 'Unilateral' + 'Bilateral' is not necessarily equal to 'Any' in the below table. The difference observed in 'Nuclear Opacification' in 15 mg group, comes from that 1 participant who had Unilateral worsening at a given visit and a Bilateral worsening at another visit. Therefore, this participant was counted as 'Unilateral', 'Bilateral' and counted only once in 'Any'. Results are based on the TE period. |
| Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier | Criteria for potentially clinically significant abnormalities: Hemoglobin: less than or equal to (\<=) 115 grams per liter (g/L) \[Male\]; \<=95 g/L \[Female\]; greater than or equal to (\>=) 185 g/L \[Male\]; \>=165 g/L \[Female\]; Decrease from baseline \>=20 g/L; Hematocrit: \<=0.37 volume/volume (v/v) \[Male\]; \<=0.32 v/v \[Female\]; \>=0.55 v/v \[Male\]; \>=0.5 v/v \[Female\]; Erythrocyte (red blood cells \[RBC\]): \>=6\*10\^12 per liter (/L); Platelet: less than (\<) 100\*10\^9/L; \>=700\*10\^9/L; Leukocyte (white blood cells \[WBC\]): \<3\*10\^9/L \[Non-Black\]; \<2\*10\^9/L \[Black\], \>=16\*10\^9/L; Neutrophils: \<1.5\*10\^9/L \[Non-Black\]; \<1\*10\^9/L \[Black\]; Lymphocytes: greater than (\>) 4\*10\^9/L, Monocytes: \>0.7\*10\^9/L; Basophils: \>0.1\*10\^9/L; and Eosinophils: \>0.5\*10\^9/L or \>upper limit of normal (ULN) (if ULN \>=0.5\*10\^9/L). |
| Annualized Slope of Change in Total Kidney Volume (TKV) From Baseline to Month 18: Combined Stage 1 and Stage 2 | From Baseline to Month 18 | Total kidney volume is a measure for assessing disease progression in participants with ADPKD, a prognostic biomarker of renal function decline and progression to end-stage renal disease. Kidney volume was assessed using MRI. The annualized slope of change in TKV (in % per year) in each treatment group was obtained from the back-transformation of the mean slope of log10-transformed TKV obtained from the linear mixed effect model. The model included fix effects of treatment (venglustat 15 mg, venglustat 8 mg or placebo), mayo imaging classification (as per randomization stratification factor: class 1C versus 1D versus 1E), time (as continuous variable in years), treatment \* time interaction and mayo imaging classification \* time interaction and included random intercept and slope. |
Countries
Argentina, Australia, Austria, Belgium, Canada, China, Czechia, Denmark, France, Germany, Israel, Italy, Japan, Netherlands, Poland, Portugal, Romania, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom, United States
Participant flow
Recruitment details
This study was conducted at 93 sites that enrolled participants in 23 countries. A total of 478 participants were enrolled from 04 October 2018 to 01 June 2021. Study was conducted in 2 stages: Stage 1 and Stage 2.
Pre-assignment details
Participants who completed 24 months of treatment in either Stage 1 or Stage 2 of EFC15392 had option to enroll in an open-label long-term extension study LTS15823 (NCT ID: NCT04705051).
Participants by arm
| Arm | Count |
|---|---|
| Stage 1- Placebo Participants from Stage 1 were randomized to receive 2 capsules of placebo matched to venglustat once daily for treatment period of 24 months. | 78 |
| Stage 1- Venglustat 8 mg Participants from Stage 1 were randomized to receive venglustat 8 mg (i.e., 2 capsules of 4 mg) once daily for treatment period of 24 months. | 78 |
| Stage 1- Venglustat 15 mg Participants from Stage 1 were randomized to receive 1 capsule of venglustat 15 mg and 1 capsule of placebo matched to venglustat once daily for treatment period of 24 months. | 80 |
| Stage 2- Placebo Participants from Stage 2 were randomized to receive 1 capsule of placebo matched to venglustat once daily for treatment period of 24 months. | 123 |
| Stage 2- Venglustat 15 mg Participants from Stage 2 were randomized to receive 1 capsule of venglustat 15 mg once daily for treatment period of 24 months. | 119 |
| Total Title | 478 |
| Total | 956 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Stage 1 (24 Months) | Adverse Event | 2 | 2 | 4 | 0 | 0 |
| Stage 1 (24 Months) | Lack of Efficacy | 2 | 0 | 0 | 0 | 0 |
| Stage 1 (24 Months) | Other-Unspecified | 1 | 2 | 0 | 0 | 0 |
| Stage 1 (24 Months) | Poor compliance to protocol | 1 | 0 | 0 | 0 | 0 |
| Stage 1 (24 Months) | Progressive disease | 0 | 0 | 1 | 0 | 0 |
| Stage 1 (24 Months) | Study terminated by sponsor | 54 | 59 | 56 | 0 | 0 |
| Stage 1 (24 Months) | Withdrawal by Subject | 6 | 5 | 7 | 0 | 0 |
| Stage 2 (24 Months) | Adverse Event | 0 | 0 | 0 | 1 | 2 |
| Stage 2 (24 Months) | Other-Unspecified | 0 | 0 | 0 | 2 | 3 |
| Stage 2 (24 Months) | Randomized and not treated | 0 | 0 | 0 | 1 | 0 |
| Stage 2 (24 Months) | Study terminated by sponsor | 0 | 0 | 0 | 119 | 110 |
| Stage 2 (24 Months) | Withdrawal by Subject | 0 | 0 | 0 | 0 | 4 |
Baseline characteristics
| Characteristic | Stage 1- Placebo | Total Title | Stage 2- Venglustat 15 mg | Stage 2- Placebo | Stage 1- Venglustat 15 mg | Stage 1- Venglustat 8 mg |
|---|---|---|---|---|---|---|
| Age, Continuous | 42.6 years STANDARD_DEVIATION 6 | 42.2 years STANDARD_DEVIATION 6.5 | 42.1 years STANDARD_DEVIATION 6.7 | 41.7 years STANDARD_DEVIATION 6.9 | 43.6 years STANDARD_DEVIATION 5.7 | 41.7 years STANDARD_DEVIATION 6.9 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 27 Participants | 188 Participants | 55 Participants | 52 Participants | 27 Participants | 27 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 3 Participants | 0 Participants | 2 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 4 Participants | 0 Participants | 2 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 48 Participants | 280 Participants | 64 Participants | 66 Participants | 52 Participants | 50 Participants |
| Sex: Female, Male Female | 37 Participants | 196 Participants | 48 Participants | 46 Participants | 34 Participants | 31 Participants |
| Sex: Female, Male Male | 41 Participants | 282 Participants | 71 Participants | 77 Participants | 46 Participants | 47 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 78 | 0 / 78 | 0 / 80 | 0 / 122 | 0 / 119 |
| other Total, other adverse events | 42 / 78 | 46 / 78 | 48 / 80 | 32 / 122 | 48 / 119 |
| serious Total, serious adverse events | 8 / 78 | 15 / 78 | 19 / 80 | 6 / 122 | 7 / 119 |
Outcome results
Primary
Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) From Baseline to Month 24: Combined Stage 1 and Stage 2
An eGFR was used to measure level of kidney function and determine the stage of kidney disease in ADPKD participants. Baseline eGFR was defined for each participant as the average of eGFR values assessed prior or equal to first dose of study drug or randomization for participants randomized and not exposed. Annualized rate of change in eGFR in each treatment group was obtained from the linear mixed effect model including the fixed categorical effects of treatment group (venglustat 15 mg, venglustat 8 mg or placebo), mayo imaging classification (as per interactive response technology \[IRT\]: 1C, 1D, 1E), time (as continuous variable in years), treatment-by-time, mayo imaging classification-by-time, and included random intercept and slope.
Time frame: From Baseline to Month 24
Population: Analysis was performed on Combined Stage 1 and Stage 2 ITT population that included all participants with an eGFR between 45 and 89.9 mL/min/1.73 m\^2 at screening who are randomized in Stage 1 or Stage 2 and were analyzed according to the intervention allocated by randomization (venglustat 15 mg, venglustat 8 mg or placebo). Data for this outcome measure (OM) was planned to be collected and analyzed for combined Stage 1 and Stage 2 population as pre-specified in protocol.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Stage 1- Placebo | Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) From Baseline to Month 24: Combined Stage 1 and Stage 2 | -2.40 mL/min/1.73 m^2/year |
| Stage 1- Venglustat 8 mg | Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) From Baseline to Month 24: Combined Stage 1 and Stage 2 | -4.82 mL/min/1.73 m^2/year |
| Stage 1- Venglustat 15 mg | Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) From Baseline to Month 24: Combined Stage 1 and Stage 2 | -4.89 mL/min/1.73 m^2/year |
p-value: =0.000595% CI: [35.63, 233.72]linear mixed effect model
p-value: =0.000295% CI: [39.54, 236.45]linear mixed effect model
Primary
Annualized Slope of Change in Total Kidney Volume (TKV) From Baseline to Month 18: Stage 1
Total kidney volume is a measure for assessing disease progression in participants with ADPKD, a prognostic biomarker of renal function decline and progression to end-stage renal disease. Kidney volume was assessed using magnetic resonance imaging (MRI). The annualized slope of change in TKV (in percentage \[%\] per year) in each treatment group was obtained from the back-transformation of the mean slope of log10-transformed TKV obtained from the linear mixed effect model. The model included fix effects of treatment (venglustat 15 mg, venglustat 8 mg or placebo), mayo imaging classification (as per randomization stratification factor: class 1C versus 1D versus 1E), time (as continuous variable in years), treatment \* time interaction and mayo imaging classification \* time interaction and included random intercept and slope.
Time frame: From Baseline to Month 18
Population: Analysis was performed on Stage 1 intent-to-treat (ITT) population that includes all participants randomized in Stage 1 and were analyzed according to the intervention allocated by randomization (venglustat 15 mg, venglustat 8 mg or placebo). Here, 'Overall number of participants analyzed' signifies participants who were evaluable for the outcome measure.
| Arm | Measure | Value (GEOMETRIC_LEAST_SQUARES_MEAN) |
|---|---|---|
| Stage 1- Placebo | Annualized Slope of Change in Total Kidney Volume (TKV) From Baseline to Month 18: Stage 1 | 6.35 percent change in TKV/year |
| Stage 1- Venglustat 8 mg | Annualized Slope of Change in Total Kidney Volume (TKV) From Baseline to Month 18: Stage 1 | 7.71 percent change in TKV/year |
| Stage 1- Venglustat 15 mg | Annualized Slope of Change in Total Kidney Volume (TKV) From Baseline to Month 18: Stage 1 | 6.38 percent change in TKV/year |
p-value: =0.136795% CI: [-5.77, 58.22]linear mixed effect model
p-value: =0.981295% CI: [-24.57, 33.36]linear mixed effect model
Secondary
Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Month 24: Stage 1
An eGFR was used to measure level of kidney function and determine the stage of kidney disease in ADPKD participants. Baseline eGFR was defined for each participant as the average of eGFR values assessed prior or equal to first dose of study drug or randomization for participants randomized and not exposed. Annualized rate of change in eGFR was obtained from the linear mixed effect model including the fixed categorical effects of treatment group, mayo imaging classification (as per IRT), time (as continuous variable in years), treatment-by-time, mayo imaging classification-by-time, and included random intercept and slope. Due to early termination of study for futility, the two-steps analysis initially planned was not applicable, then the annualized rate of change from baseline in eGFR in Stage 1 population were assessed using all data available up to database lock (i.e., including Month 24 assessment). As this is a slope, it allowed to have more data and to reduce variability.
Time frame: From Baseline to Month 24
Population: Analysis was performed on Stage 1 ITT population.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Stage 1- Placebo | Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Month 24: Stage 1 | -3.14 mL/min/1.73 m^2/year |
| Stage 1- Venglustat 8 mg | Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Month 24: Stage 1 | -4.74 mL/min/1.73 m^2/year |
| Stage 1- Venglustat 15 mg | Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Month 24: Stage 1 | -4.59 mL/min/1.73 m^2/year |
p-value: =0.019795% CI: [7.01, 125.45]linear mixed effect model
p-value: =0.033795% CI: [3.21, 119.01]linear mixed effect model
Secondary
Annualized Slope of Change in Total Kidney Volume (TKV) From Baseline to Month 18: Combined Stage 1 and Stage 2
Total kidney volume is a measure for assessing disease progression in participants with ADPKD, a prognostic biomarker of renal function decline and progression to end-stage renal disease. Kidney volume was assessed using MRI. The annualized slope of change in TKV (in % per year) in each treatment group was obtained from the back-transformation of the mean slope of log10-transformed TKV obtained from the linear mixed effect model. The model included fix effects of treatment (venglustat 15 mg, venglustat 8 mg or placebo), mayo imaging classification (as per randomization stratification factor: class 1C versus 1D versus 1E), time (as continuous variable in years), treatment \* time interaction and mayo imaging classification \* time interaction and included random intercept and slope.
Time frame: From Baseline to Month 18
Population: As no post-baseline MRI data were collected in Stage 2 due to early study discontinuation, the analysis of TKV in Combined Stage 1 and Stage 2 was not done.
Secondary
Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2
The Beck Depression Inventory-II (BDI-II) is a 21-item questionnaire used to assess depression. Most items are rated on a 4-point scale from 0 to 3, and a few items are rated on a 7-point scale. Individual item scores are added to get a total BDI-II score from 0 to 63. The higher the total score, the more severe the depression, and the lower the total score, the less severe the depression.
Time frame: Baseline, Months 3, 6, 9, 12, 15, 18, 21, and 24, Last on-treatment value up to last IMP + 1 day (anytime during the maximum duration of 25 months)
Population: Analysis was performed on extended Combined Stage 1 and Stage 2 safety population. Here, number analyzed signifies participants with available data for each specified category. Data for this OM was planned to be collected and analyzed for combined Stage 1 and Stage 2 population as pre-specified in protocol.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Stage 1- Placebo | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 12 | -1.9 score on a scale | Standard Deviation 3.9 |
| Stage 1- Placebo | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Last on-treatment value | -0.5 score on a scale | Standard Deviation 5.1 |
| Stage 1- Placebo | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 18 | -1.0 score on a scale | Standard Deviation 4.9 |
| Stage 1- Placebo | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 21 | 1.0 score on a scale | Standard Deviation 9.5 |
| Stage 1- Placebo | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Baseline | 4.0 score on a scale | Standard Deviation 4.7 |
| Stage 1- Placebo | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 3 | -0.1 score on a scale | Standard Deviation 4 |
| Stage 1- Placebo | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 24 | -0.3 score on a scale | Standard Deviation 0.5 |
| Stage 1- Placebo | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 6 | -0.6 score on a scale | Standard Deviation 4.2 |
| Stage 1- Placebo | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 9 | -0.3 score on a scale | Standard Deviation 4.8 |
| Stage 1- Placebo | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 15 | -1.5 score on a scale | Standard Deviation 4.4 |
| Stage 1- Venglustat 8 mg | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Baseline | 3.0 score on a scale | Standard Deviation 4.1 |
| Stage 1- Venglustat 8 mg | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 12 | 0.2 score on a scale | Standard Deviation 4.7 |
| Stage 1- Venglustat 8 mg | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 6 | 0.9 score on a scale | Standard Deviation 4.2 |
| Stage 1- Venglustat 8 mg | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Last on-treatment value | 0.1 score on a scale | Standard Deviation 4 |
| Stage 1- Venglustat 8 mg | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 3 | 0.7 score on a scale | Standard Deviation 4 |
| Stage 1- Venglustat 8 mg | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 18 | 0.5 score on a scale | Standard Deviation 3 |
| Stage 1- Venglustat 8 mg | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 15 | -0.1 score on a scale | Standard Deviation 4.4 |
| Stage 1- Venglustat 8 mg | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 24 | 0.8 score on a scale | Standard Deviation 2.2 |
| Stage 1- Venglustat 8 mg | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 21 | -0.1 score on a scale | Standard Deviation 1.3 |
| Stage 1- Venglustat 8 mg | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 9 | 0.1 score on a scale | Standard Deviation 3.7 |
| Stage 1- Venglustat 15 mg | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 21 | 1.1 score on a scale | Standard Deviation 2.8 |
| Stage 1- Venglustat 15 mg | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 24 | 0.3 score on a scale | Standard Deviation 1.7 |
| Stage 1- Venglustat 15 mg | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Last on-treatment value | 0.3 score on a scale | Standard Deviation 4.6 |
| Stage 1- Venglustat 15 mg | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 3 | 0.7 score on a scale | Standard Deviation 4.3 |
| Stage 1- Venglustat 15 mg | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 6 | 0.3 score on a scale | Standard Deviation 3.9 |
| Stage 1- Venglustat 15 mg | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 9 | 0.7 score on a scale | Standard Deviation 4.9 |
| Stage 1- Venglustat 15 mg | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 12 | 1.5 score on a scale | Standard Deviation 5.3 |
| Stage 1- Venglustat 15 mg | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 15 | -0.3 score on a scale | Standard Deviation 4 |
| Stage 1- Venglustat 15 mg | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Change at Month 18 | 0.0 score on a scale | Standard Deviation 3.5 |
| Stage 1- Venglustat 15 mg | Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2 | Baseline | 3.4 score on a scale | Standard Deviation 4.1 |
Secondary
Change in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI-SF)-Item 3 Scale Score From Baseline to Month 18: Stage 1
The BFI-SF is a 10-item, validated, self-administered questionnaire that was originally developed to assess fatigue severity. The 10-items were measured on a 0-10 scale, with 0 being 'does not interfere' and 10 being 'completely interferes.' BFI - Item 3 asks participants to 'Please rate your fatigue (weariness, tiredness) by circling the one number that best describes your worst level of fatigue during the past 24 hours. The NRS ranged from 0 (no fatigue) to 10 (worst imaginable fatigue). Higher global scores were associated with more severe fatigue. LS means and SE were estimated from MMRM analysis.
Time frame: From Baseline to Month 18
Population: Analysis was performed on Stage 1 ITT population. Here, 'Overall number of participants analyzed' signifies participants who were evaluable for the outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Stage 1- Placebo | Change in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI-SF)-Item 3 Scale Score From Baseline to Month 18: Stage 1 | -0.26 score on a scale | Standard Error 0.23 |
| Stage 1- Venglustat 8 mg | Change in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI-SF)-Item 3 Scale Score From Baseline to Month 18: Stage 1 | -0.10 score on a scale | Standard Error 0.25 |
| Stage 1- Venglustat 15 mg | Change in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI-SF)-Item 3 Scale Score From Baseline to Month 18: Stage 1 | -0.64 score on a scale | Standard Error 0.24 |
p-value: =0.624595% CI: [-0.506, 0.839]Mixed effect model with repeated measure
p-value: =0.256795% CI: [-1.044, 0.281]Mixed effect model with repeated measure
Secondary
Change in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI-SF)-Item 3 Scale Score From Baseline to Month 24: Combined Stage 1 and Stage 2
The BFI-SF is a 10-item, validated, self-administered questionnaire that was originally developed to assess fatigue severity. The 10-items were measured on a 0-10 scale, with 0 being 'does not interfere' and 10 being 'completely interferes.' BFI - Item 3 asks participants to Please rate your fatigue (weariness, tiredness) by circling the one number that best describes your worst level of fatigue during the past 24 hours. The NRS ranged from 0 (no fatigue) to 10 (worst imaginable fatigue). Higher global scores were associated with more severe fatigue. LS means and SE were estimated from MMRM analysis.
Time frame: From Baseline to Month 24
Population: Analysis was performed on Combined Stage 1 and Stage 2 ITT population. Here, 'Overall number of participants analyzed' signifies participants who were evaluable for the outcome measure. Data for this OM was planned to be collected and analyzed for combined Stage 1 and Stage 2 population as pre-specified in protocol.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Stage 1- Placebo | Change in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI-SF)-Item 3 Scale Score From Baseline to Month 24: Combined Stage 1 and Stage 2 | 0.02 score on a scale | Standard Error 0.38 |
| Stage 1- Venglustat 8 mg | Change in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI-SF)-Item 3 Scale Score From Baseline to Month 24: Combined Stage 1 and Stage 2 | -0.85 score on a scale | Standard Error 0.55 |
| Stage 1- Venglustat 15 mg | Change in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI-SF)-Item 3 Scale Score From Baseline to Month 24: Combined Stage 1 and Stage 2 | -0.51 score on a scale | Standard Error 0.38 |
p-value: =0.202395% CI: [-2.232, 0.485]Mixed effect model with repeated measure
p-value: =0.320595% CI: [-1.61, 0.537]Mixed effect model with repeated measure
Secondary
Change in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score From Baseline to Month 18: Stage 1
The BPI-SF is a validated, self-administered questionnaire designed to measure a participant's perceived level of pain. The BPI-SF consisted of 15 items that use a numeric rating scale (NRS) to assess pain severity and pain interference in the past 24 hours and the past week. BPI-SF Item 3 asks participants to Please rate your pain by marking the box beside the number that best describes your pain at its worst in the past 24 hours. The NRS ranged from 0 (no pain) to 10 (worst imaginable pain), where higher scores indicates greater intensity of pain. Least-squares (LS) means, and standard errors (SE) were estimated from mixed-effect model with repeated measures (MMRM) analysis.
Time frame: From Baseline to Month 18
Population: Analysis was performed on Stage 1 ITT population. Here, 'Overall number of participants analyzed' signifies participants who were evaluable for the outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Stage 1- Placebo | Change in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score From Baseline to Month 18: Stage 1 | -0.09 score on a scale | Standard Error 0.15 |
| Stage 1- Venglustat 8 mg | Change in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score From Baseline to Month 18: Stage 1 | 0.01 score on a scale | Standard Error 0.17 |
| Stage 1- Venglustat 15 mg | Change in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score From Baseline to Month 18: Stage 1 | -0.35 score on a scale | Standard Error 0.16 |
p-value: =0.637495% CI: [-0.342, 0.556]Mixed effect model with repeated measure
p-value: =0.25695% CI: [-0.689, 0.185]Mixed effect model with repeated measure
Secondary
Change in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score From Baseline to Month 24: Combined Stage 1 and Stage 2
The BPI-SF is a validated, self-administered questionnaire designed to measure a participant's perceived level of pain. The BPI-SF consisted of 15 items that use a NRS to assess pain severity and pain interference in the past 24 hours and the past week. BPI-SF Item 3 asks participants to Please rate your pain by marking the box beside the number that best describes your pain at its worst in the past 24 hours. The NRS ranged from 0 (no pain) to 10 (worst imaginable pain), where higher scores indicate greater intensity of pain. LS means and SE were estimated from MMRM analysis.
Time frame: From Baseline to Month 24
Population: Analysis was performed on Combined Stage 1 and Stage 2 ITT population. Here, 'Overall number of participants analyzed' signifies participants who were evaluable for the outcome measure. Data for this OM was planned to be collected and analyzed for combined Stage 1 and Stage 2 population as pre-specified in protocol.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Stage 1- Placebo | Change in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score From Baseline to Month 24: Combined Stage 1 and Stage 2 | -0.20 score on a scale | Standard Error 0.23 |
| Stage 1- Venglustat 8 mg | Change in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score From Baseline to Month 24: Combined Stage 1 and Stage 2 | -0.31 score on a scale | Standard Error 0.36 |
| Stage 1- Venglustat 15 mg | Change in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score From Baseline to Month 24: Combined Stage 1 and Stage 2 | -0.36 score on a scale | Standard Error 0.23 |
p-value: =0.7995% CI: [-0.971, 0.747]Mixed effect model with repeated measure
p-value: =0.632295% CI: [-0.808, 0.5]Mixed effect model with repeated measure
Secondary
Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2
Physical examination included: Head, Heart, Lung, Abdomen, Musculo/Skeletal, Skin, and Mental Status. Abnormality in physical examination was based on investigator's discretion. Results are based on the treatment emergent period which was defined as time from the first IMP administration up to the last IMP administration in EFC15392 study + 30 days or up to the first visit in LTS15823 study, whichever comes earlier.
Time frame: Baseline, Month 18, Month 24
Population: Analysis was performed on extended Combined Stage 1 and Stage 2 safety population. Here, number analyzed signifies participants with available data for each specified category. Data for this OM was planned to be collected and analyzed for combined Stage 1 and Stage 2 population as pre-specified in protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Head | 1 Participants |
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Mental Status | 1 Participants |
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Skin | 7 Participants |
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Mental Status | 0 Participants |
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Skin | 1 Participants |
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Mental Status | 0 Participants |
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Musculo/Skeletal | 0 Participants |
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Abdomen | 2 Participants |
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Head | 0 Participants |
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Abdomen | 0 Participants |
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Lung | 0 Participants |
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Heart | 0 Participants |
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Heart | 2 Participants |
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Lung | 0 Participants |
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Lung | 0 Participants |
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Musculo/Skeletal | 0 Participants |
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Heart | 0 Participants |
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Abdomen | 15 Participants |
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Skin | 0 Participants |
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Head | 0 Participants |
| Stage 1- Placebo | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Musculo/Skeletal | 5 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Abdomen | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Head | 1 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Heart | 1 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Abdomen | 1 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Musculo/Skeletal | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Mental Status | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Lung | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Abdomen | 12 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Musculo/Skeletal | 1 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Skin | 2 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Mental Status | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Head | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Heart | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Lung | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Skin | 1 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Mental Status | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Head | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Heart | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Lung | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Musculo/Skeletal | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Skin | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Musculo/Skeletal | 4 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Abdomen | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Mental Status | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Abdomen | 24 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Mental Status | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Head | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Lung | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Musculo/Skeletal | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Heart | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Heart | 1 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Heart | 1 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Lung | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Head | 4 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Head | 1 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Skin | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Lung | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Mental Status | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Musculo/Skeletal | 1 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Baseline: Skin | 3 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 24: Abdomen | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2 | Month 18: Skin | 0 Participants |
Secondary
Number of Participants With Potentially and Clinically Significant Abnormalities: Urinalysis: Combined Stage 1 and Stage 2
Criteria for potentially clinically significant abnormalities: Urine pH: \<=4.6 and \>=8.
Time frame: From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier
Population: Analysis was performed on extended Combined Stage 1 and Stage 2 safety population. Here, number analyzed signifies participants with available data for each specified category. Data for this OM was planned to be collected and analyzed for combined Stage 1 and Stage 2 population as pre-specified in protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Stage 1- Placebo | Number of Participants With Potentially and Clinically Significant Abnormalities: Urinalysis: Combined Stage 1 and Stage 2 | Urine pH: <=4.6 | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially and Clinically Significant Abnormalities: Urinalysis: Combined Stage 1 and Stage 2 | Urine pH: >=8 | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially and Clinically Significant Abnormalities: Urinalysis: Combined Stage 1 and Stage 2 | Urine pH: <=4.6 | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially and Clinically Significant Abnormalities: Urinalysis: Combined Stage 1 and Stage 2 | Urine pH: >=8 | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially and Clinically Significant Abnormalities: Urinalysis: Combined Stage 1 and Stage 2 | Urine pH: <=4.6 | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially and Clinically Significant Abnormalities: Urinalysis: Combined Stage 1 and Stage 2 | Urine pH: >=8 | 0 Participants |
Secondary
Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2
Criteria for potentially clinically significant abnormalities: Sitting Systolic Blood Pressure: \<=95 millimeters of Mercury (mmHg) and decrease from Baseline \>=20 mmHg; \>=160 mmHg and increase from Baseline \>=20 mmHg; Sitting Diastolic Blood Pressure: \<=45 mmHg and decrease from Baseline \>=10 mmHg, \>=110 mmHg and increase from Baseline \>=10 mmHg; Sitting Heart Rate: \<=50 beats/minute and decrease from Baseline \>=20 beats/minute; \>=120 beats/minute and increase from Baseline \>=20 beats/minute; and Weight: \>=5% decrease from Baseline; \>=5% increase from Baseline.
Time frame: From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier
Population: Analysis was performed on extended Combined Stage 1 and Stage 2 safety population. Here, number analyzed signifies participants with available data for each specified category. Data for this OM was planned to be collected and analyzed for combined Stage 1 and Stage 2 population as pre-specified in protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Stage 1- Placebo | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Sitting Heart Rate: <=50 beats/min and decrease from Baseline >=20 beats/min | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Sitting Systolic Blood Pressure: >=160 mmHg and increase from Baseline >=20 mmHg | 2 Participants |
| Stage 1- Placebo | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Sitting Heart Rate: >=120 beats/min and increase from Baseline >=20 beats/min | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Weight: >=5% decrease from Baseline | 11 Participants |
| Stage 1- Placebo | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Weight: >=5% increase from Baseline | 15 Participants |
| Stage 1- Placebo | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Sitting Diastolic Blood Pressure: <= 45 mmHg and decrease from Baseline >=10 mmHg | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Sitting Diastolic Blood Pressure: >=110 mmHg and increase from Baseline >=10 mmHg | 2 Participants |
| Stage 1- Placebo | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Sitting Systolic Blood Pressure: <=95 mmHg and decrease from Baseline >=20 mmHg | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Sitting Heart Rate: <=50 beats/min and decrease from Baseline >=20 beats/min | 2 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Sitting Heart Rate: >=120 beats/min and increase from Baseline >=20 beats/min | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Sitting Diastolic Blood Pressure: >=110 mmHg and increase from Baseline >=10 mmHg | 4 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Weight: >=5% decrease from Baseline | 4 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Weight: >=5% increase from Baseline | 9 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Sitting Systolic Blood Pressure: <=95 mmHg and decrease from Baseline >=20 mmHg | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Sitting Systolic Blood Pressure: >=160 mmHg and increase from Baseline >=20 mmHg | 3 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Sitting Diastolic Blood Pressure: <= 45 mmHg and decrease from Baseline >=10 mmHg | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Sitting Diastolic Blood Pressure: <= 45 mmHg and decrease from Baseline >=10 mmHg | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Sitting Systolic Blood Pressure: >=160 mmHg and increase from Baseline >=20 mmHg | 10 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Sitting Heart Rate: <=50 beats/min and decrease from Baseline >=20 beats/min | 2 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Sitting Heart Rate: >=120 beats/min and increase from Baseline >=20 beats/min | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Sitting Systolic Blood Pressure: <=95 mmHg and decrease from Baseline >=20 mmHg | 1 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Weight: >=5% increase from Baseline | 15 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Weight: >=5% decrease from Baseline | 13 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2 | Sitting Diastolic Blood Pressure: >=110 mmHg and increase from Baseline >=10 mmHg | 7 Participants |
Secondary
Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2
Criteria for potentially clinically significant abnormalities: Glucose: \<=3.9 millimoles per liter (mmol/L) and \<lower limit of normal (LLN): \>=11.1 mmol/L (unfasted); \>=7 mmol/L (fasted); Albumin:\<=25 g/L; Sodium: \<=129 mmol/L; \>=160 mmol/L; Potassium: \<3 mmol/L; \>=5.5 mmol/L; Chloride: \<80 mmol/L, \>115 mmol/L; Creatinine: \>=150 micro millimoles per liter (mcmol/L) (Adults); \>=30% change from Baseline; \>=100% change from Baseline, Urea Nitrogen: \>=17 mmol/L; Alanine Aminotransferase (ALT): \>3 ULN; Aspartate Aminotransferase (AST): \>3 ULN; Alkaline Phosphatase: \>1.5 ULN; Total Bilirubin: \>1.5 ULN, \>2 ULN; ALT \>3 ULN and Bilirubin \>2 ULN; and Direct Bilirubin \>35% Bilirubin and Bilirubin \>1.5 ULN.
Time frame: From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier
Population: Analysis was performed on extended Combined Stage 1 and Stage 2 safety population. Here, number analyzed signifies participants with available data for each specified category. Data for this OM was planned to be collected and analyzed for combined Stage 1 and Stage 2 population as pre-specified in protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | ALT >3 ULN and Bilirubin >2 ULN | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Chloride: >115 mmol/L | 1 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Creatinine: >=150 mcmol/L (Adults) | 50 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Creatinine: >=100% change from Baseline | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Glucose: <=3.9 mmol/L and <LLN | 17 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Total Bilirubin: >2 ULN | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Urea Nitrogen: >=17 mmol/L | 1 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Total Bilirubin: >1.5 ULN | 2 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | ALT: > 3 ULN | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Sodium: <=129 mmol/L | 1 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Glucose: >=11.1 mmol/L (unfasted); >=7 mmol/L (fasted) | 10 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Creatinine: >=30% change from Baseline | 12 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Potassium: <3 mmol/L | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Alkaline Phosphatase: >1.5 ULN | 3 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Sodium: >=160 mmol/L | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Potassium: >=5.5 mmol/L | 5 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | AST: >3 ULN | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Direct Bilirubin >35% Bilirubin and Bilirubin >1.5 ULN | 2 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Chloride: <80 mmol/L | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Albumin: <=25 g/L | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Albumin: <=25 g/L | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Glucose: <=3.9 mmol/L and <LLN | 5 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Glucose: >=11.1 mmol/L (unfasted); >=7 mmol/L (fasted) | 5 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Sodium: <=129 mmol/L | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Potassium: <3 mmol/L | 1 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Potassium: >=5.5 mmol/L | 5 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Chloride: <80 mmol/L | 1 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Creatinine: >=100% change from Baseline | 1 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Urea Nitrogen: >=17 mmol/L | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | AST: >3 ULN | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Total Bilirubin: >1.5 ULN | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Total Bilirubin: >2 ULN | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | ALT >3 ULN and Bilirubin >2 ULN | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Sodium: >=160 mmol/L | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Chloride: >115 mmol/L | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Creatinine: >=150 mcmol/L (Adults) | 21 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | ALT: > 3 ULN | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Creatinine: >=30% change from Baseline | 18 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Alkaline Phosphatase: >1.5 ULN | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Direct Bilirubin >35% Bilirubin and Bilirubin >1.5 ULN | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Potassium: >=5.5 mmol/L | 11 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Potassium: <3 mmol/L | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | ALT: > 3 ULN | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Sodium: >=160 mmol/L | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Glucose: >=11.1 mmol/L (unfasted); >=7 mmol/L (fasted) | 19 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Chloride: >115 mmol/L | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | AST: >3 ULN | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Glucose: <=3.9 mmol/L and <LLN | 12 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Creatinine: >=150 mcmol/L (Adults) | 70 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Sodium: <=129 mmol/L | 3 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Alkaline Phosphatase: >1.5 ULN | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Urea Nitrogen: >=17 mmol/L | 6 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Direct Bilirubin >35% Bilirubin and Bilirubin >1.5 ULN | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Total Bilirubin: >1.5 ULN | 1 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Creatinine: >=100% change from Baseline | 4 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Creatinine: >=30% change from Baseline | 25 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Total Bilirubin: >2 ULN | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Chloride: <80 mmol/L | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | Albumin: <=25 g/L | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2 | ALT >3 ULN and Bilirubin >2 ULN | 0 Participants |
Secondary
Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2
Criteria for potentially clinically significant abnormalities: Heart Rate: \<50 beats/minute; \<50 beats/minute and decrease from Baseline \>=20 beats/minute; \<40 beats/minute; \<40 beats/minute and decrease from Baseline \>=20 beats/min; \<30 beats/minute; \>90 beats/minute; \>90 beats/minute and increase from Baseline \>=20 beats/minute; \>100 beats/minute; \>100 beats/minute and increase from Baseline \>=20 beats/minute; \>120 beats/minute; \>120 beats/minute, increase from Baseline \>=20 beats/minute; PR Interval: \>200 milliseconds (msec); \>200 msec and increase from Baseline \>=25%; \>220 msec, \>240 msec; QRS Interval: \>110 msec; \>110 msec and increase from Baseline \>=25%; \>120 msec; \>120 msec and increase from Baseline \>=25%; QT Interval: \>500 msec; QT corrected for heart rate (QTc) Bazett: \>450 msec; \>480 msec; increase from Baseline (30-60) msec; increase from Baseline \>60 msec; QTc Fridericia: \>450 msec; \>480 msec; increase from Baseline (30-60) msec and increase from Baseline \> 60 msec.
Time frame: From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier
Population: Analysis was performed on extended Combined Stage 1 and Stage 2 safety population. Here, number analyzed signifies participants with available data for each specified category. Data for this OM was planned to be collected and analyzed for combined Stage 1 and Stage 2 population as pre-specified in protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: <50 beats/min and decrease from Baseline >=20 beats/min | 1 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: <50 beats/min | 7 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Bazett: >480 msec | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Bazett: Increase from Baseline [30-60] msec | 13 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QRS Interval: >120 msec | 2 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Fridericia: >450 msec | 4 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: >90 beats/min and increase from Baseline >=20 beats/min | 2 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Bazett: Increase from Baseline >60 msec | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: >100 beats/min | 1 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QRS Interval: > 110 msec and increase from Baseline >=25% | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: <40 beats/min | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QRS Interval: >110 msec | 11 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Fridericia: Increase from Baseline >60 msec | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | PR Interval: >240 msec | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: >120 beats/min | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | PR Interval: >200 msec and increase from Baseline >=25% | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: >100 beats/min and increase from Baseline >=20 beats/min | 1 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | PR Interval: >200 msec | 8 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: >120 beats/min and increase from Baseline >=20 beats/min | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Fridericia: Increase from Baseline [30-60] msec | 5 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Bazett: >450 msec | 5 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: <40 beats/min and decrease from Baseline >=20 beats/min | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: <30 beats/min | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | PR Interval: >220 msec | 1 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Fridericia: >480 msec | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: >90 beats/min | 4 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QT Interval: >500 msec | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QRS Interval: >120 msec and increase from Baseline >=25% | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QRS Interval: >120 msec and increase from Baseline >=25% | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: <50 beats/min | 6 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: <40 beats/min | 1 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: >90 beats/min | 2 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: >100 beats/min | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: >100 beats/min and increase from Baseline >=20 beats/min | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: >120 beats/min and increase from Baseline >=20 beats/min | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | PR Interval: >200 msec | 2 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | PR Interval: >200 msec and increase from Baseline >=25% | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | PR Interval: >220 msec | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QRS Interval: >110 msec | 4 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Bazett: >450 msec | 2 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Fridericia: >480 msec | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Fridericia: Increase from Baseline [30-60] msec | 1 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: <50 beats/min and decrease from Baseline >=20 beats/min | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: <40 beats/min and decrease from Baseline >=20 beats/min | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: <30 beats/min | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: >90 beats/min and increase from Baseline >=20 beats/min | 2 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: >120 beats/min | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | PR Interval: >240 msec | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QRS Interval: > 110 msec and increase from Baseline >=25% | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QRS Interval: >120 msec | 1 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QT Interval: >500 msec | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Bazett: >480 msec | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Bazett: Increase from Baseline [30-60] msec | 1 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Bazett: Increase from Baseline >60 msec | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Fridericia: >450 msec | 1 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Fridericia: Increase from Baseline >60 msec | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: <40 beats/min and decrease from Baseline >=20 beats/min | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QRS Interval: >110 msec | 10 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: <50 beats/min and decrease from Baseline >=20 beats/min | 1 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Fridericia: >450 msec | 2 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QRS Interval: > 110 msec and increase from Baseline >=25% | 1 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Bazett: Increase from Baseline >60 msec | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: <30 beats/min | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Bazett: >450 msec | 3 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QRS Interval: >120 msec and increase from Baseline >=25% | 1 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QRS Interval: >120 msec | 3 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Fridericia: >480 msec | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QT Interval: >500 msec | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: >120 beats/min and increase from Baseline >=20 beats/min | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: <40 beats/min | 1 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Bazett: >480 msec | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Fridericia: Increase from Baseline [30-60] msec | 3 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Bazett: Increase from Baseline [30-60] msec | 5 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: >90 beats/min and increase from Baseline >=20 beats/min | 2 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: <50 beats/min | 13 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: >120 beats/min | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: >100 beats/min and increase from Baseline >=20 beats/min | 1 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | PR Interval: >200 msec | 10 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: >100 beats/min | 2 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | PR Interval: >200 msec and increase from Baseline >=25% | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | PR Interval: >220 msec | 2 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | Heart Rate: >90 beats/min | 3 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | QTc Fridericia: Increase from Baseline >60 msec | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2 | PR Interval: >240 msec | 0 Participants |
Secondary
Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2
Criteria for potentially clinically significant abnormalities: Hemoglobin: less than or equal to (\<=) 115 grams per liter (g/L) \[Male\]; \<=95 g/L \[Female\]; greater than or equal to (\>=) 185 g/L \[Male\]; \>=165 g/L \[Female\]; Decrease from baseline \>=20 g/L; Hematocrit: \<=0.37 volume/volume (v/v) \[Male\]; \<=0.32 v/v \[Female\]; \>=0.55 v/v \[Male\]; \>=0.5 v/v \[Female\]; Erythrocyte (red blood cells \[RBC\]): \>=6\*10\^12 per liter (/L); Platelet: less than (\<) 100\*10\^9/L; \>=700\*10\^9/L; Leukocyte (white blood cells \[WBC\]): \<3\*10\^9/L \[Non-Black\]; \<2\*10\^9/L \[Black\], \>=16\*10\^9/L; Neutrophils: \<1.5\*10\^9/L \[Non-Black\]; \<1\*10\^9/L \[Black\]; Lymphocytes: greater than (\>) 4\*10\^9/L, Monocytes: \>0.7\*10\^9/L; Basophils: \>0.1\*10\^9/L; and Eosinophils: \>0.5\*10\^9/L or \>upper limit of normal (ULN) (if ULN \>=0.5\*10\^9/L).
Time frame: From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier
Population: Analysis was performed on extended Combined Stage 1 and Stage 2 safety population. Here, number analyzed signifies participants with available data for specified category. Data for this OM was planned to be collected and analyzed for combined Stage 1 and Stage 2 population as pre-specified in protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Platelet: >=700*10^9/L | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Hematocrit: <=0.37 v/v (Male); <=0.32 v/v (Female) | 40 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Hemoglobin: <=115 g/L (Male); <=95 g/L (Female) | 7 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Eosinophils: >0.5*10^9/L or >ULN | 7 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Hemoglobin: Decrease from baseline >=20 g/L | 4 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Hemoglobin: >=185 g/L (Male); >=165 g/L (Female) | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Monocytes >0.7*10^9/L | 6 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Leukocyte (WBC): <3*10^9/L (Non-Black); <2*10^9/L (Black) | 1 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Platelet: <100*10^9/L | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Leukocyte (WBC): >=16*10^9/L | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Erythrocyte (RBC): >=6 * 10^12/L | 1 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Hematocrit: >=0.55 v/v (Male); >=0.5 v/v (Female) | 0 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Neutrophils: <1.5*10^9/L (Non-Black); <1*10^9/L (Black) | 1 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Basophils: >0.1*10^9/L | 33 Participants |
| Stage 1- Placebo | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Lymphocytes: >4*10^9/L | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Leukocyte (WBC): >=16*10^9/L | 2 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Platelet: <100*10^9/L | 2 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Platelet: >=700*10^9/L | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Neutrophils: <1.5*10^9/L (Non-Black); <1*10^9/L (Black) | 1 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Eosinophils: >0.5*10^9/L or >ULN | 2 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Hemoglobin: <=115 g/L (Male); <=95 g/L (Female) | 3 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Hemoglobin: >=185 g/L (Male); >=165 g/L (Female) | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Hemoglobin: Decrease from baseline >=20 g/L | 7 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Hematocrit: <=0.37 v/v (Male); <=0.32 v/v (Female) | 20 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Hematocrit: >=0.55 v/v (Male); >=0.5 v/v (Female) | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Erythrocyte (RBC): >=6 * 10^12/L | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Leukocyte (WBC): <3*10^9/L (Non-Black); <2*10^9/L (Black) | 2 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Lymphocytes: >4*10^9/L | 1 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Monocytes >0.7*10^9/L | 3 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Basophils: >0.1*10^9/L | 5 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Hematocrit: >=0.55 v/v (Male); >=0.5 v/v (Female) | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Hemoglobin: Decrease from baseline >=20 g/L | 5 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Monocytes >0.7*10^9/L | 7 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Leukocyte (WBC): <3*10^9/L (Non-Black); <2*10^9/L (Black) | 4 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Platelet: <100*10^9/L | 1 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Neutrophils: <1.5*10^9/L (Non-Black); <1*10^9/L (Black) | 3 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Erythrocyte (RBC): >=6 * 10^12/L | 1 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Hemoglobin: >=185 g/L (Male); >=165 g/L (Female) | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Hemoglobin: <=115 g/L (Male); <=95 g/L (Female) | 5 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Lymphocytes: >4*10^9/L | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Eosinophils: >0.5*10^9/L or >ULN | 1 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Platelet: >=700*10^9/L | 0 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Hematocrit: <=0.37 v/v (Male); <=0.32 v/v (Female) | 42 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Leukocyte (WBC): >=16*10^9/L | 1 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2 | Basophils: >0.1*10^9/L | 8 Participants |
Secondary
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs): Combined Stage 1 and Stage 2
An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. SAE was any untoward medical occurrence that at any dose: results in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was a medically important event. TEAEs were AEs that developed, worsened or became serious during the TE period (defined as the time from the first IMP administration up to the last IMP administration in EFC15392 study + 30 days or up to the first visit in LTS15823 study, whichever comes earlier).
Time frame: From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier
Population: Analysis was performed on extended Combined Stage 1 and Stage 2 safety population that included all participants with an eGFR between 45 and 89.9 mL/min/1.73 m\^2 at screening who were randomized in Stage 1 or Stage 2 and who took at least one dose or part of a dose of IMP, analyzed according to treatment actually received. Data for this OM was planned to be collected and analyzed for combined Stage 1 and Stage 2 population as pre-specified in protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Stage 1- Placebo | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs): Combined Stage 1 and Stage 2 | TEAEs | 128 Participants |
| Stage 1- Placebo | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs): Combined Stage 1 and Stage 2 | TESAEs | 14 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs): Combined Stage 1 and Stage 2 | TEAEs | 65 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs): Combined Stage 1 and Stage 2 | TESAEs | 15 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs): Combined Stage 1 and Stage 2 | TEAEs | 143 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs): Combined Stage 1 and Stage 2 | TESAEs | 26 Participants |
Secondary
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs): Stage 1
An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. A serious adverse event (SAE) was any untoward medical occurrence that at any dose: results in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was a medically important event. TEAEs were AEs that developed, worsened or became serious during the treatment-emergent (TE) period (defined as the time from the first investigational medicinal product \[IMP\] administration up to the last IMP administration in EFC15392 study + 30 days or up to the first visit in LTS15823 study, whichever comes earlier).
Time frame: From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier
Population: Analysis was performed on Stage 1 safety population that included all participants randomized in Stage 1 who took at least one dose or part of a dose of the double-blind IMP, analyzed according to the treatment actually received (venglustat 15 mg, venglustat 8 mg, or placebo)
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Stage 1- Placebo | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs): Stage 1 | TEAEs | 62 Participants |
| Stage 1- Placebo | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs): Stage 1 | TESAEs | 8 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs): Stage 1 | TEAEs | 65 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs): Stage 1 | TESAEs | 15 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs): Stage 1 | TEAEs | 70 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs): Stage 1 | TESAEs | 19 Participants |
Secondary
Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2
Worsening of lens opacity classification system (LOCS) III score or World Health Organization (WHO) grade in nuclear opacification, cortical opacification and posterior subcapsular opacification were assessed for 'Any eye', 'Unilateral' and 'Bilateral' separately. A participant could be counted in all the 3 categories. In each category, the worst case was taken into account. To be evaluable for 'Any', a participant had to have at least one eye evaluable, whereas, for 'Unilateral' and 'Bilateral', a participant had to have both eyes evaluable. Therefore, the sum of 'Unilateral' + 'Bilateral' is not necessarily equal to 'Any' in the below table. The difference observed in 'Nuclear Opacification' in 15 mg group, comes from that 1 participant who had Unilateral worsening at a given visit and a Bilateral worsening at another visit. Therefore, this participant was counted as 'Unilateral', 'Bilateral' and counted only once in 'Any'. Results are based on the TE period.
Time frame: From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier
Population: Analysis was performed on extended Combined Stage 1 and Stage 2 safety population. Here, number analyzed signifies participants with available data for each specified category. Data for this OM was planned to be collected and analyzed for combined Stage 1 and Stage 2 population as pre-specified in protocol. TE period: time from first IMP administration up to the last IMP administration in EFC15392 study + 30 days or up to the first visit in LTS15823 study, whichever comes earlier.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Stage 1- Placebo | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score >= 0.8 or WHO grade >= 1.0 in cortical opacification: Bilateral | 2 Participants |
| Stage 1- Placebo | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score>=0.5 or WHO grade >= 1.0 in posterior subcapsular opacification:Any eye | 2 Participants |
| Stage 1- Placebo | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score>=0.5 or WHO grade >=1.0 in posterior subcapsularopacification:Unilateral | 0 Participants |
| Stage 1- Placebo | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score>=0.5 or WHO grade >=1.0 in posterior subcapsular opacification:Bilateral | 2 Participants |
| Stage 1- Placebo | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score >= 0.5 or WHO grade >= 1.0 in nuclear opacification: Any eye | 8 Participants |
| Stage 1- Placebo | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score >= 0.5 or WHO grade >= 1.0 in nuclear opacification: Unilateral | 0 Participants |
| Stage 1- Placebo | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score >= 0.5 or WHO grade >= 1.0 in nuclear opacification: Bilateral | 8 Participants |
| Stage 1- Placebo | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score >= 0.8 or WHO grade >= 1.0 in cortical opacification: Unilateral | 1 Participants |
| Stage 1- Placebo | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score >= 0.8 or WHO grade >= 1.0 in cortical opacification: Any eye | 4 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score >= 0.5 or WHO grade >= 1.0 in nuclear opacification: Any eye | 3 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score >= 0.8 or WHO grade >= 1.0 in cortical opacification: Bilateral | 4 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score >= 0.8 or WHO grade >= 1.0 in cortical opacification: Unilateral | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score>=0.5 or WHO grade >= 1.0 in posterior subcapsular opacification:Any eye | 2 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score>=0.5 or WHO grade >=1.0 in posterior subcapsularopacification:Unilateral | 1 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score >= 0.5 or WHO grade >= 1.0 in nuclear opacification: Unilateral | 0 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score >= 0.8 or WHO grade >= 1.0 in cortical opacification: Any eye | 4 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score>=0.5 or WHO grade >=1.0 in posterior subcapsular opacification:Bilateral | 1 Participants |
| Stage 1- Venglustat 8 mg | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score >= 0.5 or WHO grade >= 1.0 in nuclear opacification: Bilateral | 3 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score>=0.5 or WHO grade >=1.0 in posterior subcapsular opacification:Bilateral | 2 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score >= 0.5 or WHO grade >= 1.0 in nuclear opacification: Unilateral | 4 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score >= 0.8 or WHO grade >= 1.0 in cortical opacification: Any eye | 4 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score >= 0.8 or WHO grade >= 1.0 in cortical opacification: Bilateral | 3 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score >= 0.5 or WHO grade >= 1.0 in nuclear opacification: Bilateral | 6 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score >= 0.8 or WHO grade >= 1.0 in cortical opacification: Unilateral | 1 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score>=0.5 or WHO grade >= 1.0 in posterior subcapsular opacification:Any eye | 3 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score>=0.5 or WHO grade >=1.0 in posterior subcapsularopacification:Unilateral | 1 Participants |
| Stage 1- Venglustat 15 mg | Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2 | Worsening of LOCS III score >= 0.5 or WHO grade >= 1.0 in nuclear opacification: Any eye | 9 Participants |
Secondary
Pharmacokinetics: Plasma Concentration of Venglustat: Stage 1
Venglustat plasma concentrations was determined using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Data for this outcome measure was not planned to be collected and analyzed for placebo arm.
Time frame: Day 1: 3 hours Post-Dose, Month 1: Pre-Dose and 3 hours Post-Dose, Month 6: Pre-Dose, Month 18: Pre-Dose
Population: Analysed on Stage 1 pharmacokinetic (PK) population that included all participants randomized in Stage 1 who took at least one dose of study drug and had at least one post-baseline PK assessment; analyzed according to the intervention they actually received. Here, number analyzed signifies participants with available data for each specified category.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Stage 1- Placebo | Pharmacokinetics: Plasma Concentration of Venglustat: Stage 1 | Month 1: Pre-Dose | 54.7 nanograms per milliliter | Standard Deviation 19.2 |
| Stage 1- Placebo | Pharmacokinetics: Plasma Concentration of Venglustat: Stage 1 | Months 6: Pre-Dose | 57.5 nanograms per milliliter | Standard Deviation 23.5 |
| Stage 1- Placebo | Pharmacokinetics: Plasma Concentration of Venglustat: Stage 1 | Month 1: 3 hours Post-Dose | 82.1 nanograms per milliliter | Standard Deviation 24.7 |
| Stage 1- Placebo | Pharmacokinetics: Plasma Concentration of Venglustat: Stage 1 | Months 18: Pre-Dose | 58.3 nanograms per milliliter | Standard Deviation 22 |
| Stage 1- Placebo | Pharmacokinetics: Plasma Concentration of Venglustat: Stage 1 | Day 1: 3 hours Post-Dose | 27.8 nanograms per milliliter | Standard Deviation 11.9 |
| Stage 1- Venglustat 8 mg | Pharmacokinetics: Plasma Concentration of Venglustat: Stage 1 | Months 18: Pre-Dose | 120.3 nanograms per milliliter | Standard Deviation 73.1 |
| Stage 1- Venglustat 8 mg | Pharmacokinetics: Plasma Concentration of Venglustat: Stage 1 | Day 1: 3 hours Post-Dose | 50.9 nanograms per milliliter | Standard Deviation 22.5 |
| Stage 1- Venglustat 8 mg | Pharmacokinetics: Plasma Concentration of Venglustat: Stage 1 | Month 1: Pre-Dose | 103.9 nanograms per milliliter | Standard Deviation 50.2 |
| Stage 1- Venglustat 8 mg | Pharmacokinetics: Plasma Concentration of Venglustat: Stage 1 | Month 1: 3 hours Post-Dose | 154.6 nanograms per milliliter | Standard Deviation 61.1 |
| Stage 1- Venglustat 8 mg | Pharmacokinetics: Plasma Concentration of Venglustat: Stage 1 | Months 6: Pre-Dose | 106.2 nanograms per milliliter | Standard Deviation 56.3 |
Secondary
Pharmacokinetics: Plasma Concentration of Venglustat: Stage 2
Venglustat plasma concentrations was determined using a validated LC-MS/MS method. Data for this outcome measure was not planned to be collected and analyzed for placebo arm.
Time frame: Month 1: Pre-dose and 3 hours Post-dose
Population: Analysis was performed on Stage 2 PK population that included all participants with an eGFR between 45 and 89.9 mL/min/1.73 m\^2 at screening who were randomized in Stage 2, who took at least one dose of study drug and who had at least one post-baseline PK assessment. Participants were analyzed according to study drug they actually received. Here, number analyzed signifies participants with available data for each specified category.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Stage 1- Placebo | Pharmacokinetics: Plasma Concentration of Venglustat: Stage 2 | Month 1: Pre-Dose | 109.3 nanograms per milliliter | Standard Deviation 60.7 |
| Stage 1- Placebo | Pharmacokinetics: Plasma Concentration of Venglustat: Stage 2 | Month 1: 3 hours Post-Dose | 163.5 nanograms per milliliter | Standard Deviation 79.7 |